XL 20q12/20qter

Deletion Probe

Order Number
Package Size
100 µl


XL 20q12/20qter

This product has been replaced by XL 20q12/20qter plus. Order Number D-5121-100-OG

Clinical Details

The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

A chromosome 20q deletion is associated with about 5 % of primary MDS. The majority of cases has an interstitial deletion between 20q11.2 and q13.3. Isochromosome of the long arm of chromosome 20 with loss of interstitial material [ider(20q)] is a variant of deletion of chromosome 20q. Amplification of genes included in retained regions associated with loss of tumor suppressor genes in deleted regions could explain cell tumor progression and possibly the less favorable prognosis of ider(20q) compared with del(20q).

Clinical Applications

  • Myelodysplastic Syndrome (MDS)
  • Acute Myelogenous Leukemia (AML)


XL 20q12/20qter

XL 20q12/20qter hybridized to lymphocytes. One normal interphase and metaphase are shown.

Expected Patterns

Expected Pattern 1

Normal Cell: Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating a deletion in 20q12.


  • Saunders et al (2005) Cancer Genet Cytogen 156:154-157
  • Smoley et al (2006) Cancer Genet Cytogenet 173:144-149
  • Douet-Gilbert et al (2008) Br J Haematol 143:716-720


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.